These data, together with those of previous studies, imply that blocking interaction of APP with either Dab or Numb, and perhaps other APP adaptor proteins (e.g., X11α, ShcC and Fe65), could be a novel therapeutical strategy for treating and/or preventing AD by lowering Aβ accumulation. This evidence concerns the gene APBA1 and Alzheimer disease.